Breast Cancer Treatment: To tARget or Not? That Is the Question.
Breast Cancer Treatment: To tARget or Not? That Is the Question.
复制标题
乳腺癌治疗：有目标还是无目标？这就是问题所在。
DOI：
10.3390/cancers15235664
复制
发表时间：
2023-11-30
期刊：
影响因子：
5.2
通讯作者：
Kotula, Leszek
中科院分区：
文献类型：
--
作者：
Stone, Alexandra;Lin, Kevin M.;Ghelani, Ghanshyam H.;Patel, Sanik;Benjamin, Sam;Graziano, Stephen;Kotula, Leszek
三阴性乳腺癌（TNBC）占诊断乳腺癌的10-20%。TNBC缺乏常见的生物标志物，例如雌激素受体（ER）、孕酮受体（PR）和人表皮生长因子受体2（HER 2）。目前正在进行研究，以确定雄激素受体（AR）在TNBC中的作用，并确定其在缺乏常见靶向受体的情况下用作有效药物靶标的能力。许多研究将联合收割机抗雄激素药物与其他化疗药物联合使用，以减少肿瘤的生长和增殖。进一步了解AR在肿瘤细胞中的作用机制，可以提高药物疗效，改善TNBC患者的预后。为了评估AR在TNBC治疗中的作用，分析了靶向AR或与其他相关信号传导分子共靶向AR的各种现有和已完成的临床试验。细胞周期蛋白依赖性激酶4/6（CDK 4/6）、细胞色素P450 17α-羟化酶/17，20-裂解酶（CYP 17裂解酶）和磷脂酰肌醇3-激酶（PI 3 K）/蛋白激酶B（AKT）信号通路是这些试验中与AR抑制剂联合治疗中使用的一些最常见的生物标志物。研究AR如何与这些分子协同作用，可以在TNBC的治疗选择方面取得越来越多的突破。以前的研究在利用AR作为TNBC全身靶向治疗的唯一药物靶标方面基本上不成功。然而，在治疗这种疾病中也缺乏其他常用的药物靶向生物标志物。因此，在使用联合治疗的临床试验中分析临床获益率（CBR）可以证明对于改善治疗选择和治疗的进展是必要的。
Triple negative breast cancer (TNBC) comprises 10–20% of diagnosed breast cancers. TNBCs are devoid of common biomarkers such as an estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Research is currently being conducted to determine the androgen receptor’s (AR) role in TNBC and determine its ability to be utilized as an effective drug target in the absence of the commonly targeted receptors. Many studies combine anti-androgen drugs with other chemotherapy to decrease tumor growth and proliferation. The further understanding of AR’s mechanism in tumor cells can improve drug efficacy as well as the prognoses of patients suffering from TNBC. To assess AR’s role in TNBC treatment, various existing and completed clinical trials targeting AR or co-targeting AR with other pertinent signaling molecules were analyzed. Cyclin-dependent kinase 4/6 (CDK4/6), cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17 lyase), and the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway were some of the most prevalent biomarkers used in combination therapy with AR inhibitors in these trials. Studying how AR functions in tandem with these molecules can have increasing breakthroughs in the treatment options for TNBC. Previous studies have been largely unsuccessful in utilizing AR as the sole drug target for systemic targeted treatment in TNBC. However, there is a lack of other commonly used drug target biomarkers in the treatment of this disease, as well. Thus, analyzing the clinical benefit rate (CBR) within clinical trials that use combination therapy can prove to be imperative to the progression of improving treatment options and prognoses.
登录
查看更多内容
影响因子：
3.7
作者：
Choupani, Edris;Madjd, Zahra;Saraygord-Afshari, Neda;Kiani, Jafar;Hosseini, Arshad
通讯作者：
Hosseini, Arshad
绝经后妇女的雄激素受体表达和乳腺癌存活。
DOI：
10.1158/1078-0432.ccr-10-2021
发表时间：
2011-04-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Hu R;Dawood S;Holmes MD;Collins LC;Schnitt SJ;Cole K;Marotti JD;Hankinson SE;Colditz GA;Tamimi RM
通讯作者：
Tamimi RM
影响因子：
16.6
作者：
Lehmann BD;Colaprico A;Silva TC;Chen J;An H;Ban Y;Huang H;Wang L;James JL;Balko JM;Gonzalez-Ericsson PI;Sanders ME;Zhang B;Pietenpol JA;Chen XS
通讯作者：
Chen XS
影响因子：
3.7
作者：
Liu CY;Lau KY;Hsu CC;Chen JL;Lee CH;Huang TT;Chen YT;Huang CT;Lin PH;Tseng LM
通讯作者：
Tseng LM
影响因子：
--
作者：
Chu, Jing;Li, Yutong;Pan, Bin
通讯作者：
Pan, Bin